(3R,4S)-2-[6-amino-2-[(2Z)-2-(cyclohexylmethylidene)hydrazinyl]-4,5-dihydropurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S)-2-[6-amino-2-[(2Z)-2-(cyclohexylmethylidene)hydrazinyl]-4,5-dihydropurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₇H₂₇N₇O₄
• 分子量: 393.4
• InChiKey: VEFJTQGZIFPOIH-HBCBBWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  161
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES
  申请人：Linden Joel M.

  公开号：US20090170803A1

  公开（公告）日：2009-07-02

  The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A 2A adenosine receptor agonist. If no anti-pathogenic agent is known the A 2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.

  本发明提供了一种治疗生物疾病的治疗方法，包括在适当的抗生素、抗真菌或抗病毒药物的有效剂量的同时使用A2A腺苷受体激动剂。如果不知道抗病原体药物，A2A激动剂可以单独使用来减轻炎症，例如在感染抗生素耐药菌或某些病毒（如SARS或埃博拉病毒）时可能发生的情况。可选地，该方法包括给予第四型PDE抑制剂。
• METHOD TO TREAT SICKLE CELL DISEASE
  申请人：Linden M. Joel

  公开号：US20080009460A1

  公开（公告）日：2008-01-10

  The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount amount of an A 2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).
• METHOD TO TREAT GASTRIC LESIONS
  申请人：Linden M. Joel

  公开号：US20080027022A1

  公开（公告）日：2008-01-31

  The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A 2A adenosine receptor agonist. The A 2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic method for treating the patient with an A 2A adenosine receptor agonist, optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor. In one embodiment, the gastric lesions are caused by, or aggravated by, the use of NSAIDS such as, for example, aspirin.
• USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY
  申请人：Li Jason Yuesheng

  公开号：US20080064653A1

  公开（公告）日：2008-03-13

  The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one A 2A receptor modulator to prevent injury to or enhance the healing of the injured cells.
• AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH IN THE LIVER FOLLOWING RESECTION
  申请人：Kranenburg Onno

  公开号：US20080262001A1

  公开（公告）日：2008-10-23

  The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A 2A adenosine receptors (ARs).